pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
SPLFIO-174
Phase 2 · small molecule · Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC
SPLFIO-174 for Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Internal code SPLFIO-174
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The George Institute
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC
- Status
- active
- Trials
- 1